Latest On Tetraphase Pharmaceuticals, Inc (TTPH):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-11-26 21:50 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-11-08 01:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 09:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 18:03 EST | Insider Trade | JOLLA PHARMACEUTICAL CO LA has indirectly acquired of 3,737,360 shares. | Buy | |
| 2020-07-27 14:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 18:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-24 19:10 EST | News | La Jolla to acquire Tetraphase Pharma | N/A | |
| 2020-06-22 17:33 EST | Insider Trade | JOLLA PHARMACEUTICAL CO LA has directly acquired 234,698 shares and currently holds 1,085,000 shares. | Buy | |
| 2020-06-22 09:09 EST | News | La Jolla Pharma makes unsolicited bid for Tetraphase Pharma | N/A | |
| 2020-06-19 13:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 05:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 06:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-10 15:19 EST | News | Melinta inks agreement for Tetraphase buy | N/A | |
| 2020-06-05 20:55 EST | News | Tetraphase up 61% premarket after Melinta emerges as top bidder | N/A | |
| 2020-06-04 16:09 EST | News | AcelRx drops bid for Tetraphase Pharma | N/A | |
| 2020-06-02 06:06 EST | Earnings Estimate | An EPS average of -$1.27 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-05-29 16:30 EST | News | Melinta tops AcelRx bid for Tetraphase Pharma | N/A | |
| 2020-05-29 16:29 EST | News | AcelRx tops Melinta with new bid for Tetraphase Pharma | N/A | |
| 2020-05-27 16:19 EST | News | AcelRx beefs up offer for Tetraphase Pharma in effort to seal the deal | N/A | |
| 2020-05-27 06:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-22 11:19 EST | News | Tetraphase on board with Melinta offer; gives notice to AcelRx | N/A | |
| 2020-05-21 02:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-15 16:38 EST | News | Melinta enters the fray for Tetraphase Pharma with takeover bid | N/A | |
| 2020-05-10 09:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-09 19:32 EST | News | Tetraphase: A Bidding War Shareholders Shouldn't Wait Around For | N/A | |
| 2020-05-08 05:06 EST | News | La Jolla Pharma makes a run at Tetraphase Pharma | N/A | |
| 2020-05-08 05:03 EST | News | Tetraphase Pharmaceuticals EPS beats by $0.32, misses on revenue | N/A | |
| 2020-05-06 06:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 06:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-12 18:14 EST | News | Tetraphase Pharmaceuticals EPS beats by $2.93, misses on revenue | N/A | |
| 2020-04-12 18:10 EST | News | AcelRx Pharma to acquire Tetraphase Pharma | N/A | |
| 2020-04-12 18:10 EST | News | AcelRx to acquire Tetraphase Pharma in all-stock deal | N/A | |
| 2020-04-12 18:08 EST | News | BMO likes Blueprint Medicines in premarket analyst action | N/A | |
| 2020-04-03 22:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-28 17:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 21:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-13 05:44 EST | Earnings Estimate | An EPS average of -$3.67 is estimated for the 2021 year. | Sell | |
| 2020-03-13 05:44 EST | Earnings Estimate | An EPS average of -$2.03 is estimated for the quarter ending on June 30, 2020. | Sell | |
| 2020-02-28 05:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 23:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 00:55 EST | Financials | Company financials have been released. | Neutral | |
About Tetraphase Pharmaceuticals, Inc (TTPH):
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
General
- Name Tetraphase Pharmaceuticals, Inc
- Symbol TTPH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 67
- Last Split Factor1:20
- Last Split Date2019-09-27
- Fiscal Year EndDecember
- IPO Date2013-03-20
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.tphase.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 1.32
- Price/Book (Most Recent Quarter) 0.59
- Enterprise Value Revenue 0.18
- Enterprise Value EBITDA 0.12
View More
Financials
- Most Recent Quarter 2020-03-31
- Operating Margin -769%
- Return on Assets -51%
- Return on Equity -139%
- Revenue 7.86 million
- Earnings Per Share -$31.10
- Revenue Per Share $1.67
- Gross Profit -17761000
- Quarterly Earnings Growth 37.9%
View More
Highlights
- Market Capitalization 16.07 million
- EBITDA -82292000
- PEG Ratio -0.02
- Analyst Target Price $1.5
- Book Value Per Share $3.78
View More
Share Statistics
- Shares Outstanding 7.3 million
- Shares Float 3.93 million
- % Held by Insiders 162%
- % Held by Institutions 45.31%
- Shares Short 219037
- Shares Short Prior Month 368938
- Short Ratio 0.16
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 2.32
- 52 Week High $3.25
- 52 Week Low $0.7
- 50 Day Moving Average 2.42
- 200 Day Moving Average 1.9
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
View More
Tetraphase Pharmaceuticals, Inc (TTPH) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Tetraphase Pharmaceuticals, Inc (TTPH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-05-07 | $N/A | -$1.31 | -$1.63 | 19.63% |
| 2019-12-31 | 2020-03-12 | $1.69 million | -$1.15 | -$5.68 | 79.75% |
| 2019-09-30 | 2019-11-13 | $3.34 million | -$6.00 | -$6.80 | 11.76% |
| 2019-06-30 | 2019-08-09 | $1.07 million | -$8.40 | -$7.47 | -12.45% |
| 2019-03-31 | 2019-05-09 | $1.27 million | -$7.20 | -$7.88 | 8.63% |
| 2018-12-31 | 2019-03-13 | $4.28 million | -$8.00 | -$8.10 | 1.23% |
| 2018-09-30 | 2018-11-07 | $1.15 million | -$7.40 | -$7.28 | -1.65% |
| 2018-06-30 | 2018-08-01 | $11.58 million | -$3.60 | -$7.36 | 51.09% |
| 2018-03-31 | 2018-05-02 | $1.89 million | -$8.40 | -$8.44 | 0.47% |
| 2017-12-31 | 2018-03-05 | $2.53 million | -$9.20 | -$12.71 | 27.62% |
| 2017-09-30 | 2017-10-31 | $4.07 million | -$12.60 | -$13.84 | 8.96% |
| 2017-06-30 | 2017-08-01 | $1.59 million | -$0.83 | -$0.74 | -12.16% |
| 2017-03-31 | 2017-05-03 | $1.49 million | -$0.79 | -$0.59 | -33.9% |
| 2016-12-31 | 2017-03-07 | $1.09 million | -$0.61 | -$0.60 | -1.67% |
| 2016-09-30 | 2016-11-02 | $850000 | -$0.58 | -$0.49 | -18.37% |
| 2016-06-30 | 2016-08-03 | $1.24 million | -$0.47 | -$0.45 | -4.44% |
| 2016-03-31 | 2016-05-03 | $1.96 million | -$0.46 | -$0.44 | -4.55% |
| 2015-12-31 | 2016-02-22 | $2.47 million | -$0.50 | -$0.44 | -13.64% |
| 2015-09-30 | 2015-11-01 | $2.86 million | -$0.49 | -$0.65 | 24.62% |
| 2015-06-30 | 2015-08-04 | $3.34 million | -$0.72 | -$0.62 | -16.13% |
| 2015-03-31 | 2015-05-05 | $3.02 million | -$0.66 | -$0.64 | -3.13% |
| 2014-12-31 | 2015-03-04 | $3.07 million | -$0.69 | -$0.59 | -16.95% |
| 2014-09-30 | 2014-11-09 | $2.29 million | -$0.55 | -$0.56 | 1.79% |
| 2014-06-30 | 2014-08-11 | $1.28 million | -$14.20 | -$10.80 | -31.48% |
| 2014-03-31 | 2014-05-11 | $2.46 million | -$10.60 | -$8.94 | -18.57% |
| 2013-12-31 | 2014-03-05 | $1.9 million | -$9.80 | -$9.23 | -6.18% |
| 2013-09-30 | 2013-11-13 | $2.17 million | -$9.80 | -$8.03 | -22.04% |
| 2013-06-30 | 2013-08-11 | $3.72 million | -$5.20 | -$3.92 | -32.65% |
| 2013-03-31 | 2013-05-12 | $2.7 million | -$6.00 | -$5.40 | -11.11% |
Tetraphase Pharmaceuticals, Inc (TTPH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Tetraphase Pharmaceuticals, Inc (TTPH) Chart:
Tetraphase Pharmaceuticals, Inc (TTPH) News:
Below you will find a list of latest news for Tetraphase Pharmaceuticals, Inc (TTPH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Tetraphase Pharmaceuticals, Inc (TTPH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Tetraphase Pharmaceuticals, Inc (TTPH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000115/0000920465-20-000115-index.htm |
| 2018-01-31 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1373707/000000000018003582/0000000000-18-003582-index.htm |
| 2018-02-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000021545718004484/0000215457-18-004484-index.htm |
| 2019-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000021545719005719/0000215457-19-005719-index.htm |
| 2019-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000021545719008302/0000215457-19-008302-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000031506618001644/0000315066-18-001644-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000089924320020621/0000899243-20-020621-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000089924320020623/0000899243-20-020623-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000089924320020624/0000899243-20-020624-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000089924320020625/0000899243-20-020625-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000089924320020626/0000899243-20-020626-index.htm |
| 2018-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000090221918000205/0000902219-18-000205-index.htm |
| 2019-11-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000091957419006801/0000919574-19-006801-index.htm |
| 2020-01-23 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000091957420000509/0000919574-20-000509-index.htm |
| 2020-01-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000091957420000685/0000919574-20-000685-index.htm |
| 2020-01-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000091957420000687/0000919574-20-000687-index.htm |
| 2020-03-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000091957420002533/0000919574-20-002533-index.htm |
| 2020-06-11 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000091957420004034/0000919574-20-004034-index.htm |
| 2020-06-30 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000091957420004380/0000919574-20-004380-index.htm |
| 2020-07-31 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000091957420004738/0000919574-20-004738-index.htm |
| 2020-07-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000091957420004739/0000919574-20-004739-index.htm |
| 2020-06-22 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000098/0000920465-20-000098-index.htm |
| 2020-06-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000102/0000920465-20-000102-index.htm |
| 2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000103/0000920465-20-000103-index.htm |
| 2020-06-22 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000104/0000920465-20-000104-index.htm |
| 2020-06-26 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000109/0000920465-20-000109-index.htm |
| 2020-07-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000115/0000920465-20-000115-index.htm |
| 2020-07-29 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000122/0000920465-20-000122-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000123/0000920465-20-000123-index.htm |
| 2020-08-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000131/0000920465-20-000131-index.htm |
| 2020-06-29 | SC 14D9 | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1373707/000095012320006482/0000950123-20-006482-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000103738920000024/0001037389-20-000024-index.htm |
| 2020-01-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000110465920009163/0001104659-20-009163-index.htm |
| 2020-06-29 | SC TO-T | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1373707/000114036120014992/0001140361-20-014992-index.htm |
| 2020-07-29 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1373707/000114036120016895/0001140361-20-016895-index.htm |
| 2018-02-01 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1373707/000119312518029281/0001193125-18-029281-index.htm |
| 2018-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518042550/0001193125-18-042550-index.htm |
| 2018-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518058550/0001193125-18-058550-index.htm |
| 2018-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518072219/0001193125-18-072219-index.htm |
| 2018-03-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518087752/0001193125-18-087752-index.htm |
| 2018-03-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1373707/000119312518099473/0001193125-18-099473-index.htm |
| 2018-04-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312518124869/0001193125-18-124869-index.htm |
| 2018-04-20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1373707/000119312518124885/0001193125-18-124885-index.htm |
| 2018-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518181735/0001193125-18-181735-index.htm |
| 2018-08-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518259715/0001193125-18-259715-index.htm |
| 2018-09-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518278524/0001193125-18-278524-index.htm |
| 2018-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518318373/0001193125-18-318373-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312518322549/0001193125-18-322549-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519074788/0001193125-19-074788-index.htm |
| 2019-03-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1373707/000119312519078261/0001193125-19-078261-index.htm |
| 2019-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312519122352/0001193125-19-122352-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1373707/000119312519122361/0001193125-19-122361-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519141401/0001193125-19-141401-index.htm |
| 2019-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519171262/0001193125-19-171262-index.htm |
| 2019-06-17 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1373707/000119312519174754/0001193125-19-174754-index.htm |
| 2019-06-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519186043/0001193125-19-186043-index.htm |
| 2019-07-23 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312519199978/0001193125-19-199978-index.htm |
| 2019-08-07 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312519215330/0001193125-19-215330-index.htm |
| 2019-08-07 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1373707/000119312519215338/0001193125-19-215338-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519216831/0001193125-19-216831-index.htm |
| 2019-08-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519235307/0001193125-19-235307-index.htm |
| 2019-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519258823/0001193125-19-258823-index.htm |
| 2019-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519260361/0001193125-19-260361-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519278417/0001193125-19-278417-index.htm |
| 2019-10-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1373707/000119312519279624/0001193125-19-279624-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312519289959/0001193125-19-289959-index.htm |
| 2020-01-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520012407/0001193125-20-012407-index.htm |
| 2020-01-23 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1373707/000119312520012432/0001193125-20-012432-index.htm |
| 2020-01-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1373707/000119312520013652/0001193125-20-013652-index.htm |
| 2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520073898/0001193125-20-073898-index.htm |
| 2020-03-16 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1373707/000119312520073899/0001193125-20-073899-index.htm |
| 2020-04-24 | DEFM14A | Definitive proxy statement relating to merger or acquisition | https://www.sec.gov/Archives/edgar/data/1373707/000119312520119057/0001193125-20-119057-index.htm |
| 2020-04-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520123046/0001193125-20-123046-index.htm |
| 2020-04-30 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520127755/0001193125-20-127755-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520135477/0001193125-20-135477-index.htm |
| 2020-05-07 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520135478/0001193125-20-135478-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520136681/0001193125-20-136681-index.htm |
| 2020-05-08 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520136682/0001193125-20-136682-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520136845/0001193125-20-136845-index.htm |
| 2020-05-08 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520136846/0001193125-20-136846-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520137724/0001193125-20-137724-index.htm |
| 2020-05-08 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520137725/0001193125-20-137725-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520140963/0001193125-20-140963-index.htm |
| 2020-05-13 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520140965/0001193125-20-140965-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520143231/0001193125-20-143231-index.htm |
| 2020-05-15 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520143232/0001193125-20-143232-index.htm |
| 2020-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520148840/0001193125-20-148840-index.htm |
| 2020-05-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520148842/0001193125-20-148842-index.htm |
| 2020-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520149329/0001193125-20-149329-index.htm |
| 2020-05-22 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520149330/0001193125-20-149330-index.htm |
| 2020-05-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520152446/0001193125-20-152446-index.htm |
| 2020-05-27 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520152447/0001193125-20-152447-index.htm |
| 2020-05-27 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520153198/0001193125-20-153198-index.htm |
| 2020-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520153623/0001193125-20-153623-index.htm |
| 2020-05-28 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520153624/0001193125-20-153624-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520155099/0001193125-20-155099-index.htm |
| 2020-05-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520155101/0001193125-20-155101-index.htm |
| 2020-05-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520155942/0001193125-20-155942-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520157392/0001193125-20-157392-index.htm |
| 2020-06-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000119312520157393/0001193125-20-157393-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520160240/0001193125-20-160240-index.htm |
| 2020-06-04 | SC14D9C | Written communication relating to third party tender offer | https://www.sec.gov/Archives/edgar/data/1373707/000119312520160241/0001193125-20-160241-index.htm |
| 2020-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520161301/0001193125-20-161301-index.htm |
| 2020-06-12 | SC TO-T | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1373707/000119312520167689/0001193125-20-167689-index.htm |
| 2020-06-12 | SC 14D9 | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312520167749/0001193125-20-167749-index.htm |
| 2020-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520174622/0001193125-20-174622-index.htm |
| 2020-06-22 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312520174648/0001193125-20-174648-index.htm |
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520177093/0001193125-20-177093-index.htm |
| 2020-06-24 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/1373707/000119312520177096/0001193125-20-177096-index.htm |
| 2020-06-24 | SC14D9C | Written communication relating to third party tender offer | https://www.sec.gov/Archives/edgar/data/1373707/000119312520177109/0001193125-20-177109-index.htm |
| 2020-06-24 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1373707/000119312520177698/0001193125-20-177698-index.htm |
| 2020-06-24 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312520177712/0001193125-20-177712-index.htm |
| 2020-07-20 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312520195519/0001193125-20-195519-index.htm |
| 2020-07-29 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1373707/000119312520201204/0001193125-20-201204-index.htm |
| 2020-07-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1373707/000119312520201936/0001193125-20-201936-index.htm |
| 2018-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118006210/0001209191-18-006210-index.htm |
| 2018-03-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118017352/0001209191-18-017352-index.htm |
| 2018-03-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118020872/0001209191-18-020872-index.htm |
| 2018-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118023582/0001209191-18-023582-index.htm |
| 2018-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118023586/0001209191-18-023586-index.htm |
| 2018-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118023588/0001209191-18-023588-index.htm |
| 2018-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118023590/0001209191-18-023590-index.htm |
| 2018-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118023594/0001209191-18-023594-index.htm |
| 2018-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118023595/0001209191-18-023595-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118034652/0001209191-18-034652-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118034653/0001209191-18-034653-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118034656/0001209191-18-034656-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118034658/0001209191-18-034658-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118034666/0001209191-18-034666-index.htm |
| 2018-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919118034670/0001209191-18-034670-index.htm |
| 2019-01-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119003290/0001209191-19-003290-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004601/0001209191-19-004601-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004602/0001209191-19-004602-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004605/0001209191-19-004605-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004607/0001209191-19-004607-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004609/0001209191-19-004609-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004610/0001209191-19-004610-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119036254/0001209191-19-036254-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119036255/0001209191-19-036255-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119036257/0001209191-19-036257-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119036259/0001209191-19-036259-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119036260/0001209191-19-036260-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119036262/0001209191-19-036262-index.htm |
| 2019-08-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119044237/0001209191-19-044237-index.htm |
| 2019-08-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119044241/0001209191-19-044241-index.htm |
| 2019-12-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119059734/0001209191-19-059734-index.htm |
| 2019-12-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000120919119060298/0001209191-19-060298-index.htm |
| 2020-01-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000121390020002196/0001213900-20-002196-index.htm |
| 2019-01-30 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000131924419000016/0001319244-19-000016-index.htm |
| 2020-07-28 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/1373707/000135445720000357/0001354457-20-000357-index.htm |
| 2020-01-28 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000002/0001373707-20-000002-index.htm |
| 2020-08-24 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000006/0001373707-20-000006-index.htm |
| 2020-08-24 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000008/0001373707-20-000008-index.htm |
| 2020-08-24 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000010/0001373707-20-000010-index.htm |
| 2020-08-25 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000012/0001373707-20-000012-index.htm |
| 2020-08-25 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000014/0001373707-20-000014-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000016/0001373707-20-000016-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000018/0001373707-20-000018-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000020/0001373707-20-000020-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000022/0001373707-20-000022-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000024/0001373707-20-000024-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000026/0001373707-20-000026-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000028/0001373707-20-000028-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000030/0001373707-20-000030-index.htm |
| 2020-08-25 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000032/0001373707-20-000032-index.htm |
| 2020-08-31 | 15-12B | Securities registration termination [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1373707/000137370720000039/0001373707-20-000039-index.htm |
| 2020-03-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000143774920005297/0001437749-20-005297-index.htm |
| 2020-03-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000143774920005317/0001437749-20-005317-index.htm |
| 2020-03-17 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000143774920005349/0001437749-20-005349-index.htm |
| 2020-03-25 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000143774920006097/0001437749-20-006097-index.htm |
| 2020-05-11 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000143774920010285/0001437749-20-010285-index.htm |
| 2020-05-12 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1373707/000143774920010428/0001437749-20-010428-index.htm |
| 2020-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1373707/000153561020000063/0001535610-20-000063-index.htm |
| 2018-03-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1373707/000156459018004528/0001564590-18-004528-index.htm |
| 2018-05-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459018010676/0001564590-18-010676-index.htm |
| 2018-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459018018883/0001564590-18-018883-index.htm |
| 2018-11-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459018028694/0001564590-18-028694-index.htm |
| 2019-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1373707/000156459019008034/0001564590-19-008034-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459019017333/0001564590-19-017333-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459019030922/0001564590-19-030922-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459019043013/0001564590-19-043013-index.htm |
| 2020-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1373707/000156459020010220/0001564590-20-010220-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1373707/000156459020022821/0001564590-20-022821-index.htm |
| 2020-08-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1373707/000182067920000002/0001820679-20-000002-index.htm |
| 2018-02-05 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1373707/999999999518000334/9999999995-18-000334-index.htm |
| 2020-08-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1373707/999999999520002292/9999999995-20-002292-index.htm |
| 2020-08-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1373707/999999999520002293/9999999995-20-002293-index.htm |
| 2020-08-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1373707/999999999520002294/9999999995-20-002294-index.htm |
| 2020-08-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1373707/999999999520002295/9999999995-20-002295-index.htm |
| 2020-08-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1373707/999999999520002296/9999999995-20-002296-index.htm |
| 2018-04-23 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1373707/999999999718005210/9999999997-18-005210-index.htm |
| 2018-05-09 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1373707/999999999718005632/9999999997-18-005632-index.htm |
| 2018-11-09 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1373707/999999999718008956/9999999997-18-008956-index.htm |
| 2018-12-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1373707/999999999718009607/9999999997-18-009607-index.htm |
| 2019-11-14 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1373707/999999999719007567/9999999997-19-007567-index.htm |
Tetraphase Pharmaceuticals, Inc (TTPH) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Tetraphase Pharmaceuticals, Inc (TTPH). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 162%Institutional Ownership: 4531%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-01-30 | Jacques Dumas | Chief ScientificOfficer | Sell | 8,750.00 | 6.22 | 54,425.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919118006210/0001209191-18-006210-index.htm |
| 2019-01-08 | Jacques Dumas | Chief ScientificOfficer | Sell | 7,497.00 | 1.60 | 11,995.20 | 0.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119003290/0001209191-19-003290-index.htm |
| 2019-12-10 | John Gordon Freund | Director | Sell | 14,507.00 | 2.19 | 31,770.33 | 0.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119060298/0001209191-19-060298-index.htm |
| 2020-06-19 | JOLLA PHARMACEUTICAL CO LA | 10% Share Holder | Buy | 234,698.00 | 2.62 | 613,993.44 | 1,085,000.00 | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000103/0000920465-20-000103-index.htm |
| 2018-05-14 | Guy Macdonald | President and Chief Executive | Buy | 2,058.00 | 131,064.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004605/0001209191-19-004605-index.htm | ||
| 2018-11-14 | Guy Macdonald | President and Chief Executive | Buy | 3,332.00 | 134,396.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004605/0001209191-19-004605-index.htm | ||
| 2019-01-06 | Christopher Watt | SVP, Finance | Buy | 2,668.00 | 21,782.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004610/0001209191-19-004610-index.htm | ||
| 2019-01-06 | Maria D Stahl | SVP and General Counsel | Buy | 18,698.00 | 23,698.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004607/0001209191-19-004607-index.htm | ||
| 2018-05-14 | Christopher Watt | SVP, Finance | Buy | 2,058.00 | 23,840.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004610/0001209191-19-004610-index.htm | ||
| 2019-12-06 | Guy Macdonald | Director | Sell | 5,734.65 | 2.25 | 12,902.96 | 250.40 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119059734/0001209191-19-059734-index.htm |
| 2018-11-14 | Christopher Watt | SVP, Finance | Buy | 3,332.00 | 27,172.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004610/0001209191-19-004610-index.htm | ||
| 2019-01-06 | Larry Tsai | Chief Medical Officer | Buy | 3,337.00 | 31,503.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004609/0001209191-19-004609-index.htm | ||
| 2019-01-06 | Larry G. Edwards | Chief Operating Officer | Buy | 4,277.00 | 32,309.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004602/0001209191-19-004602-index.htm | ||
| 2018-05-14 | Larry Tsai | Chief Medical Officer | Buy | 2,058.00 | 33,561.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004609/0001209191-19-004609-index.htm | ||
| 2018-05-14 | Larry G. Edwards | Chief Operating Officer | Buy | 2,058.00 | 34,367.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004602/0001209191-19-004602-index.htm | ||
| 2018-11-14 | Larry G. Edwards | Chief Operating Officer | Buy | 2,509.00 | 36,876.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119004602/0001209191-19-004602-index.htm | ||
| 2019-04-02 | Maria D Stahl | CBO and General Counsel | Buy | 13,913.00 | 37,611.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119044241/0001209191-19-044241-index.htm | ||
| 2020-07-28 | JOLLA PHARMACEUTICAL CO LA | 10% Share Holder | Buy | 3,737,360.00 | 2.00 | 7,474,720.00 | 4,822,360.00 | https://www.sec.gov/Archives/edgar/data/1373707/000092046520000123/0000920465-20-000123-index.htm |
| 2019-04-02 | Larry G. Edwards | President and CEO | Buy | 13,913.00 | 50,789.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119044237/0001209191-19-044237-index.htm | ||
| 2019-05-14 | Larry G. Edwards | President and CEO | Buy | 4,148.00 | 54,937.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119044237/0001209191-19-044237-index.htm | ||
| 2019-12-05 | Guy Macdonald | Director | Sell | 1,870.35 | 2.34 | 4,376.62 | 5,985.05 | https://www.sec.gov/Archives/edgar/data/1373707/000120919119059734/0001209191-19-059734-index.htm |
| 2018-01-30 | Jacques Dumas | Chief ScientificOfficer | Buy | 8,750.00 | 3.69 | 32,287.50 | 8,750.00 | https://www.sec.gov/Archives/edgar/data/1373707/000120919118006210/0001209191-18-006210-index.htm |